Stock Ratings / Health Care / VERA / dividends

MRVI (36) PRGO (41) PVLA (46) AGIO (39) ⌘ Pro Terminal →

Vera Therapeutics Inc. (Class A) (VERA) Dividend Safety Gauge & 10-Year DRIP Compounder

$30.53 -1.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $30.40

Vera Therapeutics Inc. (Class A) (VERA) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $2.20B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $30.40 (-0.43%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VERA)Realized 20D OHLCV Swing Band: ±12.2%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY VERA SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (23% of score)

FRED Regime × Technicals: 23% of 52W Range • RSI-14 at 52.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$29.88-6.7% Next Q

Q2 (-2Q)

Grade E$27.88+0.4% Next Q

Q3 (-1Q)

Grade E$27.99+9.1% Next Q

Current

Grade D-$30.53-8.5% Hist 90D α

Trajectory: E (27) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VERA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VERA currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($32.00) and Max Pain ($32.06) forces dealer call-delta covering toward $58.85.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VERA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VERA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VERA)

✓Walkthrough of VERA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VERA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.27%▼ DESCENDING CHANNEL

2026-10-30O $30.30H $31.29L $29.56C $30.53VOL 1.08M

RES: $32.33SUP: $25.69SMA50: $32.00SMA200: $36.96

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VERA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VERA Butterfly Map → + Track VERA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VERA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VERA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VERA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VERA)

Health Care Rank #811 of 1016 ⚔️ MRVI vs VERA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VERA vs. MRVI, PRGO, PVLA, AGIO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Vera Therapeutics Inc. (Class A) (VERA) ranks #811 by composite RQD confidence (35/100, grade D-) and #244 by equity capitalization ($2.20B). Within this direct 5-issuer industry benchmark cohort, VERA leads on earnings valuation at N/A trailing P/E, while PRGO leads on capital efficiency and profitability with -13.6% ROIC and 35.1% gross margin. PVLA currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with VERA at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VERA ACTIVE Vera Therapeutics Inc. (Class A)	D-	35/100	—	—	-35.0%	-1.32%	$2.20B	Benchmark Subject
MRVI Maravai LifeSciences Holdings Inc. (Class A)	D-	36/100	—	18.3%	-35.0%	-0.47%	$2.20B	/mrvi-vs-vera →
PRGO Perrigo Company plc	D-	41/100	—	35.1%	-13.6%	-0.13%	$2.21B	/prgo-vs-vera →
PVLA Palvella Therapeutics Inc.	D	46/100	—	—	-27.9%	+2.79%	$2.18B	/pvla-vs-vera →
AGIO Agios Pharmaceuticals Inc.	D-	39/100	—	88.3%	-33.8%	-2.33%	$2.22B	/agio-vs-vera →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001831828

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vera Therapeutics Inc. (Class A) (VERA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$299.6M, operating cash flow of -$241.1M, and free cash flow of -$241.7M (-78.2% YoY). On the balance sheet, VERA closed FY2025 with $734.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$299.6M	-$241.1M	-$241.7M	$734.7M	—
FY2024 (FY)	2024-12-31	$0	-$152.1M	-$134.7M	-$135.7M	$655.7M	—
FY2023 (FY)	2023-12-31	$0	-$96.0M	-$92.2M	-$92.2M	—	—

3. VERA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VERA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Vera Therapeutics Inc. (Class A) (NASDAQ: VERA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $30.53 (-1.32% 1D, market cap $2.20B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VERA ranks #811 in composite RQD confidence.

How does VERA compare to MRVI and PRGO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VERA carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MRVI (Maravai LifeSciences Holdings Inc. (Class A)) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $2.20B) and PRGO (Perrigo Company plc) posts a D- grade (41/100 RQD, P/E N/A, ROIC -13.6%, cap $2.21B). Among the 5-stock peer group, VERA leads on earnings multiple (N/A) while PRGO leads on capital efficiency (-13.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VERA?

Per VERA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001831828), Vera Therapeutics Inc. (Class A) generated $0 in revenue, -$299.6M in net income, and -$241.7M in free cash flow against $734.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VERA trading relative to its 50-day, 200-day, and 52-week technical levels?

VERA last traded at $30.53 (-1.32% on volume of 1,108,679 shares), positioning the stock -4.59% below its 50-day simple moving average ($32.00) and -17.40% below its 200-day simple moving average ($36.96). Across its 52-week range of $23.05 to $56.05, VERA sits at the 22.7% percentile with a 14-day RSI of 52.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.2% ($26.81 to $34.25).

VERA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does VERA pay a dividend and is it safe?

Vera Therapeutics Inc. (Class A) (VERA) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: VERA RQD Cockpit VERA 12M Forecast VERA Earnings & Move VERA Dividends & DRIP VERA Insiders & 13F VERA Whale Options VERA Profit Sankey VERA News & Why